Key Statistics for ACIN
|Current P/E Ratio (ttm)
Relative P/E vs.
|Earnings Per Share (EUR) (ttm)
|Est. EPS (EUR) (12/2013)
|Est. PEG Ratio
|Market Cap (M CHF)
|Shares Outstanding (M)
|30 Day Average Volume
|Dividend Indicated Gross Yield
|Cash Dividend (CHF)
|5 Year Dividend Growth
|Next Earnings Announcement
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ACIN
Acino Holding AG offers development, registration and manufacturing of generic and innovative pharmaceuticals using drug delivery technologies for which Acino also holds patents.
More Company Profile & Key Executives for ACIN
|Peter BuremaCEO/Member-Mgmt Board||Walter SaladinChief Financial Officer|
|Ruud Van AnraatChief Commercial Officer||Ulf Hergen WestphalHead:Quality/Member-Mgmt Board|
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries